Effect of trimebutine on intestinal motility and plasma motilin in the dog.
In a previous report, trimebutine was shown to induce premature periods of phase III activity in fasting dogs, and its action was blocked by naloxone. In this study, we observed that trimebutine (5 mg X kg-1 iv) could induce premature phase IIIs in canine small intestine during interdigestive and digestive periods; trimebutine-induced phase IIIs were migrating along the small intestine faster than spontaneous activity fronts and; trimebutine-induced phase IIIs were accompanied by sharp rises in concentrations of plasma motilin. To further elucidate the trimebutine-stimulatory mechanism, we verified its effects on the release of various circulating peptides that influence intestinal motility: short-interval blood sampling during trimebutine infusion revealed that plasma motilin increases induced by trimebutine preceded the beginning of phase III in proximal duodenum; and gastrin and insulin postprandial releases were abolished by trimebutine. Therefore, trimebutine, by its simultaneous but opposite effects on various peptides that individually carry positive (e.g., motilin) or negative (e.g., gastrin and insulin) influences on the generation of activity fronts, could alter the equilibrium between stimulatory and inhibitory forces in such a way that, in some circumstances (e.g., postprandial period), stimulatory mechanisms become predominant.
D000818:Animals; D001565:Benzoates / Q000494:pharmacology*; D004063:Digestion; D004285:Dogs; D004386:Duodenum / Q000502:physiology; D005260:Female; D005755:Gastrins / Q000097:blood; D005769:Gastrointestinal Motility / Q000187:drug effects*; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D007328:Insulin / Q000097:blood; D007421:Intestine, Small / Q000502:physiology; D007700:Kinetics; D009037:Motilin / Q000097:blood*; D014287:Trimebutine / Q000008:administration & dosage / Q000494:pharmacology*
D001565:Benzoates; D005755:Gastrins; D007328:Insulin; D009037:Motilin; D014287:Trimebutine